Two-arm Study, Randomised (2.:1), Open Label Phase 11/111 Study in EpCAM Positive Cancer Patients with Symptomatic Malignant Ascites Using Paracentesis Plus the Tri-Functional Antibody Removab (Anti-EpCAM X Anti-CD3 Versus Paracentesis Alo

  • Johnson, Philip (Principal Investigator)

Project Details

Short titleTwo-arm Study, Randomised (2.:1), Open Label Phase 11/111 Study in EpCAM Positive Cancer Patients with Symptomatic Malignant Ascites Using Paracentesis Plus the Tri-Functional Antibody Removab (Anti-EpCAM X Anti-CD3 Versus Paracentesis Alo
StatusFinished
Effective start/end date1/10/0431/12/06

Funding

  • Queen Elizabeth Hospital Birmingham